Mikronährstoffe in der Onkologie: Risiko und Nutzen

ZUSAMMENFASSUNG

Hintergrund: Das Interesse sowohl von betreuenden Ärzten als auch Tumorpatienten an der zusätzlichen Einnahme von Mikronährstoffen während einer onkologischen Therapie mit unterschiedlichen Intentionen nimmt zu. Dieses Update liefert deshalb eine Standortbestimmung zum zusätzlichen Einsatz von ausgewählten Mikronährstoffen während der Tumortherapie.

Methoden: Es wurde eine Literaturrecherche hinsichtlich des Einsatzes von ausgewählten Mikronährstoffen in der Onkologie, die bis 2017 in zitierfähigen Journalen erschienen sind, durchgeführt.

Ergebnisse: Daten zu Mikronährstoffen, die sowohl hinsichtlich der Lebensqualität als auch der Prognose einen Nutzen für onkologische Patienten bringen, als auch Erkenntnisse zu Mikronährstoffen, die für die Patienten keinen Benefit haben oder sogar schaden, werden präsentiert. Die gute Datenlage hinsichtlich Vitamin D und Selen erlaubt hier die Empfehlung zur Supplementation nach Spiegelbestimmung im Serum.

Schlussfolgerung: Nicht nur vorrangig onkologisch tätige Ärzte, sondern auch alle Ärzte, die Tumorpatienten mitbetreuen, sollten Kenntnisse über die wichtigsten Mikronährstoffe haben, um diese an die Patienten weiterzugeben und sie auch gezielt zum Nutzen der Patienten einzusetzen.

• Literatur

• 1 Neuhouser ML, Cheng TY, Beresford SA. et al. Red blood cell folate and plasma folate are not associated with risk of incident colorectal cancer in the Women’s Health Initiative observational study. Int J Cancer 2015; 137: 930-939
• 2 Mortensen JH, Øyen N, Fomina T. et al. Supplemental folic acid in pregnancy and childhood cancer risk. Br J Cancer 2016; 114: 71-75
• 3 Mortensen JH, Øyen N, Fomina T. et al. Supplemental folic acid in pregnancy and maternal cancer risk. Cancer Epidemiol 2015; 39: 805-811
• 4 Taylor CM, Atkinson C, Penfold C. et al. Folic acid in pregnancy and mortality from cancer and cardiovascular disease: further follow-up of the Aberdeen folic acid supplementation trial. J Epidemiol Community Health 2015; 69: 789-794
• 5 Qin T, Du M, Du H. et al. Folic acid supplements and colorectal cancer risk: meta-analysis of randomized controlled trials. Sci Rep 2015; 5: 12044
• 6 Burr NE, Hull MA, Subramanian V. J Clin Gastroenterol. Folic Acid Supplementation May Reduce Colorectal Cancer Risk in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. J Clin Gastroenterol 2017; 51: 247-253
• 7 Wien TN, Pike E, Wisløff T. et al. Cancer risk with folic acid supplements: A systematic review and meta-analysis. BMJ Open 2012; 2 (01) e000653
• 8 Kraft M, Kraft K, Gärtner S. et al. L-Carnitine supplementation in advanced pancreatic cancer (CARPAN) – a randomized multicentre trial. Nutr J 2012; 11: 52
• 9 Mochamat MückeM, Cuhls H. et al. Pharmacological treatments for fatigue associated with palliative care. Cochrane Database Syst Rev 2015; 30: CD006788
• 10 Marx W, Teleni L, Opie RS. et al. Efficacy and Effectiveness of Carnitine Supplementation for Cancer-Related Fatigue: A Systematic Literature Review and Meta-Analysis. Nutrients 2017; 9: E1224
• 11 Hershman DL, Unger JM, Crew KD. et al. Randomized double-blind placebo-controlled trial of Acetyl-L-Carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. J Clin Oncol 2013; 31: 2627-2633
• 12 Armenian SH, Gelehrter SK, Vase T. et al. Carnitine and cardiac dysfunction in childhood cancer survivors treated with anthracyclines. Cancer Epidemiol Biomarkers Prev 2014; 23: 1109-1114
• 13 Bakker MF, Peeters PH, Klaasen VM. et al. Plasma carotenoids, vitamin C, tocopherols, and retinol and the risk of breast cancer in the European Prospective Investigation into Cancer and Nutrition cohort. Am J Clin Nutr 2016; 103: 454-464
• 14 Leoncini E, Edefonti V, Hashibe M. et al. Carotenoid intake and head and neck cancer: a pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Eur J Epidemiol 2016; 31: 369-383
• 15 Nordström T, Van Blarigan EL, Ngo V. et al. Associations between circulating carotenoids, genomic instability and the risk of high-grade prostate cancer. Prostate 2016; 76: 339-348
• 16 Yu N, Su X, Wang Z, Dai B, Kang J. Association of Dietary Vitamin A and β-Carotene Intake with the Risk of Lung Cancer: A Meta-Analysis of 19 Publications. Nutrients 2015; 7: 9309-9324
• 17 Margalit DN, Kasperzyk JL, Martin NE. et al. Beta-carotene Antioxidant Use During Radiation Therapy and Prostate Cancer Outcome in the Physicians’ Health Study. J Radiat Oncol Biol Phys 2012; 83: 28-32
• 18 De Munter L, Maasland DH, van den Brandt PA, Kremer B, Schouten LJ. Vitamin and carotenoid intake and risk of head-neck cancer subtypes in the Netherlands Cohort Study. Am J Clin Nutr 2015; 102: 420-432
• 19 Edefonti V, Hashibe M, Parpinel M. et al. Natural vitamin C intake and the risk of head and neck cancer: A pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Int J Cancer 2015; 137: 448-462
• 20 Bo Y, Lu Y, Zhao Y. et al. Association between dietary vitamin C intake and risk of esophageal cancer: A dose-response meta-analysis. Int J Cancer 2015; 138: 1843-1850
• 21 Fan H, Kou J, Han D. et al. Association between vitamin C intake and the risk of pancreatic cancer: a meta-analysis of observational studies. Sci Rep 2015; 5: 13973
• 22 Bai XY, Qu X, Jiang X. et al. Association between Dietary Vitamin C Intake and Risk of Prostate Cancer: A Meta-analysis Involving 103,658 Subjects. J Cancer 2015; 6: 913-921
• 23 Shareck M, Rousseau MC, Koushik A. et al. Inverse Association between Dietary Intake of Selected Carotenoids and Vitamin C and Risk of Lung Cancer. Front Oncol 2017; 7: 23
• 24 Harris HR, Bergkvist L, Wolk A. Vitamin C intake and breast cancer mortality in a cohort of Swedish women. Br J Cancer 2013; 109: 257-264
• 25 Harris HR, Orsini N, Wolk A. Vitamin C and survival among women with breast cancer: a meta-analysis. Eur J Cancer 2014; 50: 1223-1231
• 26 Poole EM, Shu X, Caan BJ. et al. Postdiagnosis supplement use and breast cancer prognosis in the After Breast Cancer Pooling Project. Breast Cancer Res Treat 2013; 139: 529-537
• 27 Jacobs C, Hutton B, Ng T. et al. Is there a role for oral or intravenous ascorbate (vitamin C) in treating patients with cancer? A systematic review. Oncologist 2015; 20: 210-223
• 28 Heaney ML, Gardner JR, Karasavvas N. et al. Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs. Cancer Res 2008; 68: 8031-8038
• 29 Llobet D, Eritja N, Encinas M. et al. Antioxidants block proteasome inhibitor function in endometrial carcinoma cells. Anticancer Drugs 2008; 19: 115-124
• 30 Perrone G, Hideshima T, Ikeda H. et al. Ascorbic acid inhibits antitumor activity of bortezomib in vivo. Leukemia 2009; 23: 1679-1686
• 31 Pilz S, Kienreich K, Tomaschitz A. et al. Vitamin D and cancer mortality: Systematic review of prospective epidemiological Studies. Anticancer Agents Med Chem 2013; 13: 107-117
• 32 Raimondi S, Johansson H, Maisonneuve P, Gandini S. Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk. Carcinogenesis 2009; 30: 1170-1180
• 33 McCullough ML, Bostick RM, Mayo TL. Vitamin D gene pathway polymorphisms and risk of colorectal, breast, and prostate cancer. Annu Rev Nutr 2009; 29: 111-132
• 34 Yin L, Ordóñez-Mena JM, Chen T. et al. Circulating 25-hydroxyvitamin D serum concentration and total cancer incidence and mortality: A systematic review and meta-analysis. Prev Med 2013; 57: 753-764
• 35 Ma Y, Zhang P, Wang F. et al. Association between Vitamin D and risk of colorectal cancer: a systematic review of prospective studies. J Clin Oncol 2011; 29: 3775-3782
• 36 Yin L, Grandi N, Raum E. et al. Meta-analysis: longitudinal studies of serum vitamin D and colorectal cancer risk. Aliment Pharmacol Ther 2009; 30: 113-125
• 37 Zhang L, Wang S, Che X, Li X. Vitamin D and lung cancer risk: A comprehensive review and meta-analysis. Cell Physiol Biochem 2015; 36: 299-305
• 38 Stanaland M, Jiroutek MR, Holland MA. Study of the Association Between Serum Vitamin D Levels and Prostate Cancer. Military medicine 2017; 182: e1769-e1774
• 39 O‘Brien KM, Sandler DP, Taylor JA, Weinberg CR. Serum Vitamin D and Risk of Breast Cancer within Five Years. Environmental Health Perspectives 2017; 125: 077004
• 40 Andersen SW, Shu XO, Cai Q. et al. Total and Free Circulating Vitamin D and Vitamin D-Binding Protein in Relation to Colorectal Cancer Risk in a Prospective Study of African Americans. Cancer Epidemiology Biomarkers & Prevention 2017; 26: 1242-1247
• 41 Ekmekcioglu C, Haluza D, Kundi M. 25-Hydroxyvitamin D Status and Risk for Colorectal Cancer and Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Epidemiological Studies. Int J Environ Res Public Health 2017; 14: E127
• 42 Garland CF, Gorham ED. Dose-response of serum 25-hydroxyvitamin D in association with risk of colorectal cancer: A meta-analysis. J Steroid Biochem Mol Biol 2017; 168: 1-8
• 43 Ammann EM, Drake MT, Haraldsson B. et al. Incidence of hematologic malignancy and cause-specific mortality in the Women’s Health Initiative randomized controlled trial of calcium and vitamin D supplementation. Cancer 2017; 123: 4168-4177
• 44 Fedirko V, Riboli E, Tjønneland A. et al. Prediagnostic 25-Hydroxyvitamin D, VDR and CASR Polymorphisms, and Survival in Patients with Colorectal Cancer in Western European Populations. Cancer Epidemiol Biomarkers Prev 2012; 21: 582-593
• 45 Goodwin PJ, Ennis M, Pritchard KI. et al. Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. J Clin Oncol 2009; 27: 3757-3763
• 46 Maalmi H, Ordóñez-Mena JM, Schöttker B, Brenner H. Serum 25-hydroxyvitamin D levels and survival in colorectal and breast cancerpatients: systematic review and meta-analysis of prospective cohort studies. Eur J Cancer 2014; 50: 1510-1521
• 47 Mohr SB, Gorham ED, Kim J. et al Could Vitamin D sufficiency improve the survival of colorectal cancer patients?. J Steroid Biochem Mol Biol 2015; 148: 239-244
• 48 Pilz S, Kienreich K, Tomaschitz A. et al. Vitamin D and cancer mortality: systematic review of prospective epidemiological studies. Anticancer Agents Med Chem 2013; 13: 107-117
• 49 Poole EM, Shu X, Caan BJ. et al. Postdiagnosis supplement use and breast cancer prognosis in the After Breast Cancer Pooling Project. Breast Cancer Res Treat 2013; 139: 529-537
• 50 Villaseñor A, Ballard R, Ambs A. et al. Associations of serum 25-hydroxyvitamin D with overall and breast cancer-specific mortality in a multiethnic cohort of breast cancer survivors. Cancer Causes Control 2013; 24: 759-767
• 51 Vrieling A, Hein R, Abbas S. et al Serum 25-hydroxyvitamin D and postmenopausal breast cancer survival: a prospective patient cohort study. Breast Cancer Res 2011; 13 (04) R74
• 52 Zgaga L, Theodoratou E, Farrington SM. et al. Plasma Vitamin D Concentration Influences Survival Outcome After Diagnosis of Colorectal Cancer. J Clin Oncol 2014; 32: 2430-2439
• 53 Hu K, Callen DF, Li J, Zheng H. Circulating Vitamin D and Overall Survival in Breast Cancer Patients: A Dose-Response Meta-Analysis of Cohort Studies. Integr Cancer Ther 2018; 17: 217-225
• 54 Yao S, Kwan ML, Ergas IJ. et al. Association of Serum Level of Vitamin D at Diagnosis With Breast Cancer Survival: A Case-Cohort Analysis in the Pathways Study. JAMA Oncol 2017; 3: 351-357
• 55 Huang JD, Dong CH, Shao SW. et al. Circulating 25-hydroxyvitamin D level and prognosis of lung cancer patients: A systematic review and meta-analysis. Bull Cancer 2017; 104: 675-682
• 56 Maalmi H, Walter V, Jansen L. et al. Relationship of very low serum 25-hydroxyvitamin D3 levels with long-term survival in a large cohort of colorectal cancer patients from Germany. Eur J Epidemiol 2017; 32: 961-971
• 57 Bittenbring JT, Neumann F, Altmann B. et al. Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcomeof patients with diffuse large B-cell lymphoma treated with but not without rituximab. J Clin Oncol 2014; 32: 3242-3248
• 58 Tracy SI, Maurer MJ, Witzig TE. et al. Vitamin D insufficiency is associated with an increased risk of early clinical failure in follicular lymphoma. Blood Cancer J 2017; 7: e595
• 59 Hohaus S, Tisi MC, Bellesi S. et al. Vitamin D deficiency and supplementation in patients with aggressive B-cell lymphomas treated with immunochemotherapy. Cancer Med 2018; 7: 270-281
• 60 Timerman D, McEnery-Stonelake M, Joyce CJ. et al. Vitamin D deficiency is associated with a worse prognosis in metastatic melanoma. Oncotarget 2017; 8: 6873-6882
• 61 Gilbert R, Martin RM, Fraser WD. et al. Predictors of 25-hydroxyvitamin D and its association with risk factors for prostate cancer: evidence from the prostate testing for cancer and treatment study. Cancer Causes Control 2012; 23: 575-588
• 62 Rastelli AL, Taylor ME, Gao F. et al. Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial. Breast Cancer Res Treat 2011; 129: 107-116
• 63 Hoffmann MR, Senior PA, Mager DR. Vitamin D supplementation and health-related quality of life: a systematic review of the literature. J Acad Nutr Diet 2015; 115: 406-418
• 64 Mücke R, Schomburg L, Büntzel J, Gröber U, Holzhauer P, Micke O. Komplementärer Seleneinsatz in der Onkologie. Der Onkologe 2010; 16: 181-186
• 65 Bleys J, Navas-Acien A, Guallar E. Serum selenium levels and all cause, cancer, and cardiovascular mortality among US adults. Arch Intern Med 2008; 168: 404-410
• 66 Cai X, Wang C, Yu W. et al. Selenium Exposure and Cancer Risk: an Updated Meta-analysis and Meta-regression. Sci Rep 2016; 6: 19213
• 67 Lippman SM, Klein EA, Goodman PJ. et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: The selenium and vitamin E cancer prevention trial (SELECT). JAMA 2009; 301: 39-51
• 68 Mücke R, Schomburg L, Büntzel J, Kisters K, Micke O. German Working Group Trace Elements and Electrolytes in Oncology. Selenium or no selenium-that is the question in tumor patients: a new controversy. Integr Cancer Ther 2010; 9: 136-141
• 69 Geybels MS, Verhage BA, van Schooten FJ. et al. Advanced prostate cancer risk in relation to toenail selenium Levels. J Natl Cancer Inst 2013; 105: 1394-1401
• 70 Kristal AR, Darke AK, Morris JS. et al. Baseline Selenium Status and Effects of Selenium and Vitamin E Supplementation on Prostate Cancer Risk. J Natl Cancer Inst 2014; 106 djt 456
• 71 Kim Y, Wei J, Citronberg J. et al. Relation of Vitamin E and Selenium Exposure to Prostate Cancer Risk by Smoking Status: A Review and Meta-Analysis. Anticancer Res 2015; 35: 4983-4996
• 72 Cui Z, Liu D, Liu C, Liu G. Serum selenium levels and prostate cancer risk: A MOOSE-compliant meta-analysis. Medicine 2017; 96: e5944
• 73 Lener MR, Scott RJ, Wiechowska-Kozłowska A. et al. Serum Concentrations of Se and Cu in Patients Diagnosed with Pancreatic Cancer. Cancer Res Treat 2016; 48: 1056-1064
• 74 Muka T, Kraja B, Ruiter R. et al. Dietary mineral intake and lung cancer risk: the Rotterdam Study. Eur J Nutr 2017; 56: 1637-1646
• 75 Stratton MS, Algotar AM, Ranger-Moore J. et al. Oral selenium supplementation has no effect on prostate-specific antigen velocity in men undergoing active surveillance for localized prostate cancer. Cancer Prev Res (Phila) 2010; 3: 1035-1043
• 76 Kenfield SA, Van Blarigan EL, DuPre N. et al. Selenium supplementation and prostate cancer mortality. J Natl Cancer Inst 2014; 107: 360
• 77 Karp DD, Lee SJ, Keller SM. et al. Randomized, Double-Blind, Placebo-Controlled, Phase III Chemoprevention Trial of Selenium Supplementation in Patients With Resected Stage I Non-Small-Cell LungCancer: ECOG 5597. J Clin Oncol 2013; 31: 4179-4187
• 78 Lubinski J, Marciniak W, Muszynska M. et al. Serum selenium levels predict survival after breast cancer. Breast Cancer Res Treat 2018; 167: 591-598
• 79 Lubiński J, Marciniak W, Muszynska M. et al. Serum selenium levels and the risk of progression of laryngeal cancer. PLoS One 2018; 13: e0184873
• 80 Son H, Lee SM, Yoon RG. et al. Effect of selenium supplementation for protection of salivary glands from iodine-131 radiation damage in patients with differentiated thyroid cancer. Hell J Nucl Med 2017; 20: 62-70